Clinical Trial Update: Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating ADI-PEG 20 plus cisplatin in metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Melanoma
• Ovarian Cancer
• Uveal Melanoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)
• CISPLATIN (cisplatin)

Snippet

Sponsor: Polaris Group | Conditions: Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors | Phase 1 | Status: COMPLETED